Lilly Sues Two Firms For Selling Unapproved Products Claiming To Contain Tirzepatide
April 1 (Reuters) - Eli Lilly and Co LLY.N:
ELI LILLY SUES STRIVE PHARMACY LLC, EMPOWER CLINIC SERVICES LLC FOR SELLING UNAPPROVED PRODUCTS CLAIMING TO CONTAIN TIRZEPATIDE
ELI LILLY: TO SEND ABOUT 50 CEASE AND DESIST LETTERS TO COMPOUNDERS AND TELEHEALTH FIRMS ASKING TO CONFIRM THEY HAVE CEASED MASS COMPOUNDING
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
TSLA Q1 Earnings Preview: Tesla Snaps 8-Week Slump—Now Buy the Dip or Wait?

AI Chip Startup Cerebras Refiles for IPO, Testing Nvidia’s Pricing Power

Intel Q1 Earnings Preview: Triple Test of CPU, 18A Yields and Foundry Orders

Allbirds Ditches Sneakers and Pivots to AI Computing - Is BIRD Stock Still Worth Buying After a 600% Surge?

Bitcoin Breaks $78,000 Amid U.S.-Iran Conflict, Can It Return to $100,000 in 2026?

Tradingkey








